A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study With a Long-Term Extension Treatment Period to Assess the Efficacy and Safety of JNJ-63733657, an Anti-tau Monoclonal Antibody, in Participants With Early Alzheimer's Disease
The primary purpose of this study is to evaluate the effect of JNJ-63733657 versus placebo on clinical decline as measured by the Integrated Alzheimer's Disease Rating Scale (iADRS), a composite of cognition and function.
Inclusion Criteria:
Exclusion Criteria:
Washington D.C., District of Columbia 20007, United States
Elk Grove Village, Illinois 60007, United States
Fujisawa-shi, 251-0038, Japan
Kamakura-shi, 247-8533, Japan
Kanzaki-gun, 842-0192, Japan
Kurashiki-shi, 7100813, Japan
Obu-shi, 474-8511, Japan
Shinjuku-ku, 162-0053, Japan
Toyonaka-shi, 560-0004, Japan
Toyonaka-shi, 5600004, Japan
Algorta - Getxo, 48993, Spain